Asosiy kontentga oʻtish
AkademIndex

Mahsulotlar

Ishlab chiquvchilar uchun

AkademBaseEkotizim uchun ochiq API
Sharh maqola

Mitochondrial dysfunction and oxidative stress in heart disease

Jessica N. PeoplesDepartment of Pediatrics, Division of Cardiovascular Biology, Emory University School of Medicine, Atlanta, GA, 30322, USAAnita SarafDepartment of Medicine, Division of Cardiology, Emory University School of Medicine, Atlanta, GA, 30322, USANasab GhazalDepartment of Pediatrics, Division of Cardiovascular Biology, Emory University School of Medicine, Atlanta, GA, 30322, USATyler T. PhamEmory College of Arts and Sciences, Emory University, Atlanta, GA, 30322, USAJennifer Q. KwongDepartment of Pediatrics, Division of Cardiovascular Biology, Emory University School of Medicine, Atlanta, GA, 30322, USA. [email protected]
2019en
ABI

Annotatsiya

Beyond their role as a cellular powerhouse, mitochondria are emerging as integral players in molecular signaling and cell fate determination through reactive oxygen species (ROS). While ROS production has historically been portrayed as an unregulated process driving oxidative stress and disease pathology, contemporary studies reveal that ROS also facilitate normal physiology. Mitochondria are especially abundant in cardiac tissue; hence, mitochondrial dysregulation and ROS production are thought to contribute significantly to cardiac pathology. Moreover, there is growing appreciation that medical therapies designed to mediate mitochondrial ROS production can be important strategies to ameliorate cardiac disease. In this review, we highlight evidence from animal models that illustrates the strong connections between mitochondrial ROS and cardiac disease, discuss advancements in the development of mitochondria-targeted antioxidant therapies, and identify challenges faced in bringing such therapies into the clinic.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar

2 ta iqtibos0 ta foydalanilgan manba